FRUZAQLA (Fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson

0
226
Biologics by McKesson has announced the US FDA approval of FRUZAQLA, an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
[McKesson Corporation]
Press Release